The effectiveness of one of the most widely used anti-coagulant drugs can be improved if genotype testing is carried out before the dose is decided, according to the findings of a new study from the University of Liverpool, and its collaborators, the Universities of Newcastle and Uppsala.
21 November, 2013
The Cancer Research Technology Pioneer Fund (CPF) has announced a collaboration with Chroma Therapeutics Ltd to develop cancer drugs targeting macrophages – white blood cells – associated with tumours.This investment by the CPF will accelerate the development of a promising ‘lead’ molecule – taking it from the laboratory into clinical trials for patients.
01 November, 2013